134 related articles for article (PubMed ID: 24504705)
1. Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease.
Uemura O; Hattori M; Hataya H; Ito S; Ito N; Akizawa T
Clin Exp Nephrol; 2014 Dec; 18(6):932-8. PubMed ID: 24504705
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
Doshi S; Chow A; Pérez Ruixo JJ
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
Lerner G; Kale AS; Warady BA; Jabs K; Bunchman TE; Heatherington A; Olson K; Messer-Mann L; Maroni BJ
Pediatr Nephrol; 2002 Nov; 17(11):933-7. PubMed ID: 12432437
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan.
Hattori M; Uemura O; Hataya H; Ito S; Hisano M; Ohta T; Fujinaga S; Kise T; Gotoh Y; Matsunaga A; Ito N; Akizawa T;
Clin Exp Nephrol; 2014 Aug; 18(4):634-41. PubMed ID: 24013765
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.
Kawakami K; Takama H; Nakashima D; Tanaka H; Uchida E; Akizawa T
Eur J Clin Pharmacol; 2009 Feb; 65(2):169-78. PubMed ID: 18807251
[TBL] [Abstract][Full Text] [Related]
6. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
[TBL] [Abstract][Full Text] [Related]
7. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
[TBL] [Abstract][Full Text] [Related]
8. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent.
Han H; Lee J; Shin D; Shin KH; Jeon H; Lim KS; Yoon SH; Shin SG; Jang IJ; Cho JY; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):373-82. PubMed ID: 24623104
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
Cheung W; Minton N; Gunawardena K
Eur J Clin Pharmacol; 2001 Aug; 57(5):411-8. PubMed ID: 11599659
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
Fang YW; Chang CH
Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
[TBL] [Abstract][Full Text] [Related]
12. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
Hudson JQ; Sameri RM
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
[TBL] [Abstract][Full Text] [Related]
13. Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.
Barnett AL; Crémieux PY
Pharmacotherapy; 2003 May; 23(5):690-3; discussion 693-4. PubMed ID: 12741447
[No Abstract] [Full Text] [Related]
14. An overview of the pharmacokinetic disposition of darbepoetin alfa.
Zamboni WC; Stewart CE
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):133S-140S. PubMed ID: 12222583
[TBL] [Abstract][Full Text] [Related]
15. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis.
Padhi D; Ni L; Cooke B; Marino R; Jang G
Clin Pharmacokinet; 2006; 45(5):503-10. PubMed ID: 16640455
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan.
Kubota M; Hiramatsu M; Yamakawa M; Fukuhara S; Morita S; Iwasaki M; Akizawa T;
Clin Exp Nephrol; 2011 Dec; 15(6):884-92. PubMed ID: 21898029
[TBL] [Abstract][Full Text] [Related]
17. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
Bommer J; Asmus G; Wenning M; Bommer G
Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
[TBL] [Abstract][Full Text] [Related]
18. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
Ling B; Walczyk M; Agarwal A; Carroll W; Liu W; Brenner R
Clin Nephrol; 2005 May; 63(5):327-34. PubMed ID: 15909591
[TBL] [Abstract][Full Text] [Related]
20. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
